OF SHARED RESOURCE The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Research Pharmacy (Oncology Invesigational Drug Service) is an integral part of the SKCCC's research efforts. The Research Pharmacy staff works in close collaboration with the SKCCC Clinical Research Office, individual investigators and the JHH Pharmacy staff to coordinate and facilitate the development, implementation and maintenance of clinical protocols. Specifically, the Research Pharmacy is responsible for the management of inventory, storage, preparation and distribution of drugs and pharmaceutics used in clinical research for the SKCCC. Clinical and operational support includes, but is not limited to, assistance and collaboration in the development/ modification and support of investigational protocols in SKCCC, ongoing responsibilities for drug accountability and regulatory compliance. The Research Pharmacy is integrated with the SKCCC and the Johns Hopkins Pharmacy Department. The resource is available to investigators and the research team for patient care issues 24 hours a day, seven days a week to support SKCCC clinical trials. The Research Pharmacy works closely with the expanding efforts of the Center to facilitate the conduction of clinical trials. Lay: The Research Pharmacy provides and oversees the pharmacy services for individuals for in clinical trials. Additionally, this resource coordinates the operational aspects of drug therapy for clinical trials. This Core Facility is administered jointly by the Johns Hopkins Hospital Investigational Drug Service (IDS) and the SKCCC. Current Grant Year Reporting Period: January 2010 to December 2010

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Zeidner, Joshua F; Zahurak, Marianna; Rosner, Gary L et al. (2015) The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma 56:128-34
Penet, Marie-France; Shah, Tariq; Bharti, Santosh et al. (2015) Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism. Clin Cancer Res 21:386-95
Sharabi, Andrew B; Nirschl, Christopher J; Kochel, Christina M et al. (2015) Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res 3:345-55
Peltonen, Karita; Colis, Laureen; Liu, Hester et al. (2014) A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 25:77-90
DeZern, Amy E; Guinan, Eva C (2014) Aplastic anemia in adolescents and young adults. Acta Haematol 132:331-9
Paller, Channing J; Wissing, Michel D; Mendonca, Janet et al. (2014) Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med 3:1322-35
Maldonado, Leonel; Teague, Jessica E; Morrow, Matthew P et al. (2014) Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 6:221ra13
Schweizer, Michael T; Antonarakis, Emmanuel S (2014) Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl 16:334-40
Huang, Peng; Ou, Ai-hua; Piantadosi, Steven et al. (2014) Formulating appropriate statistical hypotheses for treatment comparison in clinical trial design and analysis. Contemp Clin Trials 39:294-302
Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie C et al. (2014) AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res 74:5772-81

Showing the most recent 10 out of 357 publications